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Negishi cross-couplings in the synthesis of
amino acids
William D. G. Brittain * and Steven L. Cobb *
The Negishi cross-coupling is a powerful C–C bond-forming reaction widely utilised in many areas of
organic synthesis. This review details the use of Negishi cross-couplings in the synthesis of unnatural
amino acids. The application of this reaction in the preparation of aromatic, heteroaromatic, and, complex
amino acid derivatives are reviewed and presented herein.
Introduction
Negishi cross-coupling, since its original development in 1977
by Negishi and co-workers, has become a widely-utilised reac-
tion in the field of organic chemistry.1 Employing either palla-
dium or nickel as a transition metal catalyst, the Negishi cross-
coupling will form a new carbon–carbon bond between an
organic halide/triflate and an organozinc reagent.2,3 As a versa-
tile route to form carbon–carbon bonds the Negishi cross-
coupling has seen widespread use in the synthesis of many
novel structural motifs.4–6 In recent years, developments in
Negishi cross-couplings by researchers, such as Fu, has
allowed the transformation to be applied to more substrates
than ever before.7–10
One application of the Negishi cross-coupling reaction is in
the synthesis of unnatural amino acids. The formation of such
compounds is of interest to a multitude of chemical and bio-
logical research arenas. Introduction of unnatural amino acids
into peptide sequences has been used to probe protein struc-
ture and function in both in vitro11,12 and in vivo systems.13,14
Antibiotic peptides have utilized unnatural amino acids to
increase organism selectivity, potency and metabolic
stability.15
In recent years asymmetric catalysis has employed unnatural
amino acids as easily accessible chiral building blocks for the
synthesis of new ligands.16–20 For example, chiral ligands such
as PyBOX and BOX rely on the chirality aﬀorded by natural or
unnatural amino acids in their preparation and design.21–24
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With wide-ranging applications, methods to form unnatural
amino acids are without doubt important. This review gives an
overview and update25 of the synthesis and derivatisation of
amino acids through Negishi cross-couplings. Three major
classes of derivatisation are discussed: aromatic-, hetero-
aromatic and more complex unnatural amino acids. Several
mechanistic studies have been carried out on the Negishi
cross-coupling of alkylamido zinc reagents, and these are also
discussed.
Synthesis of aromatic amino acids
Aromatic amino acids have been shown to have a broad range
of utility. Aromatic amino acids have been successfully
employed in natural product synthesis,26 peptide chem-
istry27,28 and drug development.29 Therefore, facile synthesis
of aromatic amino acids is important.
The area of Negishi cross-coupling to form stereo-defined
aromatic amino acids was pioneered in the seminal work by
Jackson et al. in 1989.30 A range of novel single-enantiomer
substituted phenylalanines 3a–d were reported from the cross-
coupling between an iodozinc L-serine derivative 2 and a range
of para-substituted iodobenzenes (Scheme 1). The transform-
ation was found to be tolerant to Boc protecting groups and a
range of electron-donating (Scheme 1, 3c) and withdrawing
groups (Scheme 1, 3d) on the aryl iodide component. The
novel phenylalanine derivatives were isolated in yields of
between 35% and 65%.
Jackson and Dexter would adapt their initial Negishi cross-
coupling methods to also produce β and γ amino acids from
aspartic and glutamic acid derivatives.31 Utilising activated
zinc and Pd2(dba)3, a range of β and γ amino acids were fur-
nished in yields between 33% and 89% (Scheme 2). The scope
and reproducibility using this methodology was found to be
superior to the conditions initially used to access α amino
acids.30
Modification of serine and phenylalanine via Negishi cross-
coupling was reported by König and co-workers (Scheme 3).32
Using Rieke zinc they were able to successfully form organo-
zinc species from amino acids, which could then be coupled
with electron-rich iodoanilines and iodobenzyl amines. Using
this approach, a series of metal-chelating side chain contain-
ing unnatural amino acids 9a–e were successfully synthesised
in yields ranging between 65% and 86% (Scheme 3).
Scheme 1 Synthesis of phenylalanine derivatives via Negishi cross
coupling, Jackson and co-workers 1989.30
Scheme 2 Synthesis of aspartic and glutamic acid derivatives utilising
Negishi coupling, Jackson and Dexter, 1998.31
Scheme 3 Synthesis of novel amino acids containing metal-coordinat-
ing side chains, König and co-workers.32
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The synthesis of β2-homophenylalanine derivatives using
Negishi cross-couplings were first reported in 2008
(Scheme 4).33 The synthesis of the corresponding β3-amino
acids had already been reported in 1999,34,35 but the method-
ology had not been used to access β2-amino acids. Conjugate
addition of benzylamine to compound 10, followed by Boc pro-
tection and alkyl iodide formation, led to the protected amino
acid coupling partner 13 (Scheme 4). Cross-coupling was then
achieved using a range of aryl iodides and bromides. In the
case of nitro-substituted aryls lower yields were observed. This
was attributed to a competing zinc catalysed reduction of the
nitro groups. It was found that removal of excess zinc before
Negishi cross-coupling gave greatly improved yields, with an
increase from 24% to 45% in the case of 1-iodo-4-nitrobenzene
(Scheme 4, 14d).
In order to make the transformation as synthetically rele-
vant as possible widening the scope of the haloaryl component
of the Negishi cross-coupling was elaborated upon in 2008.36
Taking inspiration from the reported reaction of a serine
derivative 1 and a bromo-substituted naphthalene by
Szczepankiewicz et al. (Scheme 5)37 it was subsequently
demonstrated that a wide range of bromides were applicable
to the Negishi cross-coupling (Scheme 6).
Yields for the cross-coupling reaction when an aryl bromide
was employed were lower across all examples compared to
their iodo equivalents.36 However, it should be noted that aryl
bromides are often cheaper and more widely available than
their corresponding iodides.
By exploiting the diﬀerences in cross-coupling reactivity
between aromatic iodides and aromatic bromides it was
demonstrated that asymmetrical bis-amino acids could be suc-
cessfully synthesised. For example, the bis-amino acid 17
(Scheme 7) was synthesised through a double cross-coupling
process in a 21% overall yield. This was an improvement over
the previously reported palladium-catalysed Suzuki–Miyaura
coupling approach to form asymmetrical biphenyl bis-amino
acids which was found to return racemic products.38
Biarylphosphine ligands such as SPhos are known to
increase the rate and yield of palladium-catalysed reactions.39
These ligands are believed to stabilise monoligated Pd(0), and
in addition, have the ability to stabilise Pd(II) centres.39,40 It
was found that an active catalyst formed from 1 : 1 SPhos to
Pd2(dba)3 led to improved yields (compared to earlier reports)
of Negishi cross-coupled phenylalanine derivatives 3a–d
(Scheme 8).41
Interestingly it was found that when 2-iodoaniline was used
in the presence of SPhos the expected amino acid derivative
was not delivered and instead a lactam 18 was formed in good
yield (85%) (Scheme 9).
Jackson’s group built upon the observation that SPhos
improved the yields of Negishi cross-couplings. By taking
inspiration from their work on the kinetics of β-elimination,
the Boc protecting group (see mechanistic studies)42 was
Scheme 4 β2-Amino acids synthesised through Negishi cross coup-
lings, Jackson and co-workers.33
Scheme 5 Synthesis of a naphthyl-appended amino acid precursor by
Szczepankiewicz et al.37
Scheme 6 Negishi cross-couplings of aryl bromides with an iodo
serine derivative.
Scheme 7 Synthesis of a bis(amino acid) derivative via a double Negishi
cross coupling strategy.
Review Organic & Biomolecular Chemistry
12 | Org. Biomol. Chem., 2018, 16, 10–20 This journal is © The Royal Society of Chemistry 2018
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
7 
N
ov
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
on
 0
4/
01
/2
01
8 
11
:0
5:
24
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
replaced with a trifluoro-acyl (TFA) group (Scheme 10).43 The
TFA protecting group had been shown previously to perturb
the alkyl zinc halide from undergoing β-elimination, (see later
section on mechanistic studies for further information) so it
was hoped that the combination of SPhos and a TFA protect-
ing group on the zinc halide would lead to improved reaction
conditions for the synthesis of phenylethylamine derivatives.
TFA-protected zinc iodides derived from phenylalanine 19 and
valine 21 were shown to react smoothly with a range of aryl
iodides, delivering good to excellent yields of aryl appended
protected amines 20a–c/22a–c.
The synthesis of trifluoromethyl appended aromatic amino
acids were reported by Featherston and Miller (Scheme 11).44
Cross-coupling was successfully carried out between Cbz-
protected iodide 23 and a fluoro-aromatic to give 24 in a 54%
yield. The aromatic amino acid 24 was then successfully trans-
formed into the corresponding ketone through treatment with
ozone. The peptides formed in the study were found to be cata-
lytically active in the oxidation of substituted styrenes to their
corresponding epoxides. In addition to their applications in
catalysis, fluorinated amino acids have also been shown to be
useful as biophysical probes and as structural components in
peptide sequences.45
Synthesis of heteroaromatic
amino acids
Drug development and discovery often utilise heteroaromatic
cores to deliver potent biological activity,46,47 and elaboration
of heterocyclic cores with other moieties is a cornerstone of
fragment-based drug discovery (FBDD).48–50 Within this
context heteroaromatic amino acids have been shown to be
valuable building blocks for the synthesis of many biologically
active compounds.51–53 The Negishi cross-coupling is one way
in which heteroaromatic-appended amino acids can be syn-
thesised in relatively few steps with great modularity.
Synthesis of heteroaromatic amino acid derivatives formed
through Negishi cross-coupling was reported by Göbel and co-
workers.54 Negishi cross-coupling was successfully carried out
using a range of aryl bromides and iodides with oxazolidine 27
(Scheme 12). Heteroaromatics such as quinoline 30e and pyri-
midine 30f were found to be amenable to the methodology,
and the inclusion of commonly used protecting groups (Boc
and Fmoc) allowed the formed novel amino acids to be incor-
porated into longer peptide sequences by solid phase peptide
synthesis (SPPS).
A detailed study into the synthesis of ortho-substituted
nitroaromatic containing amino acid derivatives was carried
out by Tuttle et al. (Scheme 13).55 Reaction optimisation
between 1-iodo-2-nitrobenzene and iodozinc compound 31
showed that Pd(OAc)2 in combination with XPhos in a 1 : 2
ratio gave a 92% yield of the desired cross-coupling product. In
addition, it was found that 1-chloro-2-nitrobenzene was also
amenable to cross-coupling in 87% yield. A range of ortho and
multiply-substituted nitro-bromobenzenes and pyridines were
used as cross-coupling partners with iodozinc compound 31.
Yields for nitropyridines ranged between 22% and 29% whilst
nitrobenzenes ranged between 41% and 77% yield.
Using these novel protected amino acid derivatives, it was
possible to deliver the intended hydroxamic acid targets 35
Scheme 9 Unexpected lactam formation observed in the cross-coup-
ling of an iodoaniline with an iodo serine derivative.
Scheme 10 Amines prepared from amino acids by Negishi cross coup-
ling, 19 and 21 prepared from phenylalanine and valine respectively in
two steps.
Scheme 11 Synthesis of ﬂuoroaromatic amino acid precursor for appli-
cation in oxidation of substituted styrenes, Featherston and Miller.44
Scheme 8 Improved cross-coupling conditions using SPhos reported
by Jackson and co-workers.41
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(Scheme 14) (similar to the species observed in Scheme 9).
These heterocyclic motifs were of interest for their potential
biological activity and the developed methodology allowed
potential access to a library of these hydroxamic acids.
In 2014 Usuki et al. reported the improved Negishi cross-
coupling of halopyridines with an iodozinc species derived
from aspartic acid (Scheme 15).56 Previous work such as that
reported by Tuttle et al. (Scheme 13) had shown that yields for
pyridine cross-coupling products significantly lagged behind
their non-heteroaromatic equivalents.57 After extensive reac-
tion optimisation, a catalytic system of Pd2(dba)3 in combi-
nation with a P(2-furyl)3 ligand was shown to be the best for
the cross-coupling of halopyridines, with a 90% yield recorded
in the reaction between 4-iodopyridine and 36. In moving to
bromo-substituted pyridines lower yields were recorded for all
substrates, with 2–3- and 4-bromopyridines giving 44%, 33%
and 23% yields respectively. Chloropyridines, regardless of
halide position on the ring, were found to be ineﬀectual in all
Scheme 12 Synthesis of aromatic and heteroaromatic amino acids.
Scheme 13 Nitro-aromatic and heteroaromatic protected amino acid
derivatives, Tuttle et al.55
Scheme 14 Synthesis of Boc-protected nitro-aromatic-appended
amino acids and subsequent cyclisation to yield novel hydroxamic acids
by Tuttle et al.55
Scheme 15 Synthesis of pyridine-containing amino acids via Negishi
cross-couplings, Usuki et al.56
Review Organic & Biomolecular Chemistry
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cross-coupling reactions attempted. The Negishi cross-coup-
ling of halopyridines would be utilised in the synthesis of
complex pyridinium amino acids (see later section,
Scheme 24).
The ability to append furyl and thienyl functionalities onto
amino acids was reported by Cobb and co-workers in 2015
(Scheme 16).58 The synthesis of 2-thienyl-alanine was achieved
in a moderate 42% yield but this was an improvement over the
previously reported, 10% yield.59 Both Boc and Fmoc protect-
ing groups were shown to be tolerated by the cross-coupling
conditions. A Boc-protected 2-furyl derivative was subsequently
shown to be stable in a (Benzotriazol-1-yloxy)tripyrrolidino-
phosphonium hexafluorophosphate (PyBOP) mediated peptide
coupling.
Synthesis of complex amino acids
Beyond aromatic and heteroaromatic examples, the Negishi
cross-coupling reaction has been used to prepare a wide range
of complex amino acids.
The formation of biphenyl-linked amino acids and biphenyl
amino acid derivatives can be easily achieved using a cross-
coupling approach (Scheme 18).60 The synthesis of the macro-
cyclic tripeptide K1361 and a non-natural macrocyclic protease
inhibitor used this approach.62 Building upon these studies
the synthesis of biphenyl linked amino acids was reported
where a strategy of coupling iodosubstituted bi-aryls with alkyl
zinc reagents was adopted. Negishi cross-coupling was suc-
cessfully carried out between iodozinc L-serine derivative 2 and
a range of mono- and diiodo-substituted bi-phenyls.
The reaction was found to be applicable to both acyl and
benzyl protecting groups on the bi-phenyl moiety. However, it
was found that a large excess (4 equiv.) of the iodozinc species
was required in order to achieve a satisfactory yield of 65% of
the biaryl derivative 45 (Scheme 18).
Glycoproteins have been shown to be critical to cell
adhesion,63,64 diﬀerentiation65 and growth, and they have also
been used as new targets for therapeutics and diagnostics.66
Ousmer et al. utilised a Negishi cross-coupling to form a p-(C-
glucopyranosyl)phenylalanine derivative (Scheme 17).67 An
iodo-substituted phenylalanine derivative was successfully
coupled to a glucal 41 in an excellent 90% yield. This was then
further elaborated by stereo-selective hydroboration to yield
the desired glucose modified phenylalanine 43 in a 37%
overall yield.
Negishi and Suzuki–Miyaura cross-couplings were shown to
be amenable to the preparation of imidazoles derived from
amino acids (Scheme 19).68 Imidazoles derived from (S)-Ala,
(S)-Leu and (S)-Phe 46 protected with ethoxymethyl groups
gave substrates 47 which were found to readily undergo
Negishi cross-couplings to form corresponding bi-aryl systems.
Scheme 16 Furyl and thienyl-appended amino acids synthesised using
Negishi cross-coupling, Cobb and co-workers.58
Scheme 17 Synthesis of a p-(C-glucopyranosyl)phenylalanine derivative.
Scheme 18 Synthesis of a bi-aryl, bis(amino acid), Jackson and co-
workers.60
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The bi-aryl protected amines 48a–c were successfully obtained
in yields ranging from 34% to 88% (Scheme 19).
Jackson and co-workers would revisit the synthesis of the
macrocyclic peptide K1361 and expand their scope to the cyclic
peptide OF4949-III 52 in 2009.69 Building on their earlier syn-
thesis of K13 and their reported Negishi-based methodology
for bi-aryl linked amino acids,60 Jackson et al. reported an
intramolecular Negishi strategy to aﬀord K13 and a Negishi
cross-coupling key step synthesis of OF4949-III (Scheme 20).
Utilising this approach OF4949-III 52 was synthesised in 12
steps with an overall yield of 20%.
Other natural products have also been successfully syn-
thesised using Negishi cross-couplings of amino acid building
blocks as a key synthetic step. The Kapakahine family of
natural products has shown promising preliminary biological
activity against P388 murine leukemia cells and thus accessing
these compounds was of significant interest.70 The synthesis
of Kapakahine E and F, by Espejo and Rainier utilised a
Negishi cross-coupling to form a key intermediate 54 which
was subsequently taken through two end game synthetic
routes to yield the two natural products (Scheme 21).70
Negishi cross-couplings that can utilise triflates in the place
of the halide component have been widely utilised in main-
stream organic synthesis.71,72 Within the field of peptide
chemistry it was reported that a PdCl2(PPh3)2 mediated cross-
coupling between iodozinc reagents and cycloalkenyl triflates
could be carried out, but the yields obtained were only moder-
ate, ranging between 41% and 46%.73 The Negishi cross-coup-
ling of iodozinc compounds with cycloalkenyl triflate deriva-
tives was also reported by Jackson and co-workers in 2012
(Scheme 22).74 In this study, the addition of a phosphine
ligand (SPhos), in combination with a Pd2(dba)3 catalyst, gives
rise to an increase in the yield of the cross-coupling reaction
product to 70% for the cyclopentenyl and cyclohexenyl deriva-
tives 55a/b.
Yields for cycloheptenyl and cyclooctenyl products 55c/d,
however, were moderate at 54% and 58%, respectively. This led
the authors to propose that the addition of lithium chloride
could be advantageous. Lithium chloride had been shown pre-
viously to increase the yields in Stille reactions, and can
increase the reactivity of organozinc halides.75 Indeed, the
addition of 1.8 equivalents of LiCl to the Negishi cross-coup-
ling reaction mixture led to increased yields for the cyclohepte-
nyl and cyclooctenyl derivatives 55c/d, boosting yields to 62%
and 63%, respectively.
Scheme 22 Cycloalkenyl-protected amino acid derivatives, Jackson
and co-workers.74
Scheme 19 Derivitisation of imidazoles from amino acids by Negishi
cross-coupling, Marek et al.68
Scheme 20 Synthesis of cyclic peptide OF4949-III, Jackson and co-
workers.69
Scheme 21 Synthesis of Kapakahine E and F, Espejo and Rainier.70
Review Organic & Biomolecular Chemistry
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In addition to the Negishi methodology developed it was
shown that the cross-coupled product 55a could react with HF
pyridine to furnish the fluoro compound 56 in 30% isolated
yield (Scheme 23). This compound had been reported earlier
as a building block for an enzyme inhibitor.76 The previous
synthesis of compound 56 had been relatively low yielding and
had required a chiral resolution step.77 The cross-coupling
methodology therefore oﬀered a simpler and more eﬃcient
synthesis of these fluorinated motifs.
The Negishi cross-coupling of pyridines was extended to
bis-halo pyridines by Usuki and co-workers (Scheme 24).78
Utilising a di-bromo-substituted pyridine 57 a double Negishi
and Sonogashira cross-coupling was employed to garner key
intermediate 58, which was further elaborated to yield desmo-
sine 59. In the same report, a deuterated version of desmosine
was also successfully synthesised following the same cross-
coupling strategy. Desmosine is a biomarker for degradation
of elastin-containing tissues, which is a symptom of diseases
such as atherosclerosis, aortic aneurysm, cystic fibrosis and
chronic obstructive pulmonary disease (COPD).79–81 The syn-
thesis of desmosine therefore is of importance for drug discov-
ery and the rapid diagnosis of diseases such as COPD.
In 2017 Usuki and co-workers elaborted their synthesis of
Desmosine to build it into a cyclic peptide (Scheme 25).82 This
work was driven by the fact that the proposed stuctures of
elastin suggest cross-linkage through Desmosine.83,84 Through
the use of a Desmosine analogue the cross-linking motif
within elastin was hoped to be probed. Usuki and co-workers
utilised the same general strategy to build the Deomsine core
as they had previously published.78
A Sonogashira cross-coupling aﬀorded the intermediate 60
which was elaborated with a double Negishi coupling to aﬀord
intermediate 61. This intermediate was then successfully
cyclised thtough an amide coupling reaction which led to the
target compound 62. The overall synthesis gave the desired
cyclic desmosine derivative in a 0.8% overall yield from
L-alanine.
In 2017 the total synthesis of Nannocystin A 64 was
reported by Liu et al.85 Within this report a Negishi cross-coup-
ling of an iodo serine derviative was employed to build the key
fragment 63 (Scheme 26). The final natural product was deli-
vered with a longest linear sequence of 11 steps in a 5.3%
overall yield. Nannocystin A 64 has been found to possess
potent biological activity. It has been shown to be an inhibitor
of elongation factor 1 and inhibits cancer cell growth.86 The
Negishi cross-coupling reaction to form a novel amino acid
derivative was vital to access this potent natural product
synthetically.
Mechanistic studies
Several mechanistic studies have been undertaken to try and
gain fundamental knowledge of the reactivity of alkyl zinc
amino acid derivatives. Using a range of analytical techniques,
the species responsible for catalysis and mechanistic pathways
have been probed. From these studies a greater understanding
Scheme 23 Fluorination of cycloalkenyl-protected amino acid
derivatives.
Scheme 24 Synthesis of Desmosine via a Sonogashira, double Negishi
cross coupling strategy.
Scheme 25 Synthesis of a cyclic peptide derivative of Desmosine,
Usuki and co-workers.82
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of the workings of Negishi cross-couplings of iodo amino acids
has been established.
One of the major problems in the synthesis of β-amino
acids using Negishi cross-coupling is that the iodozinc cross-
coupling partner (derived from species such as aspartic or glu-
tamic acid) is intrinsically susceptible to β-elimination to form
an alkene. In order to understand these problems, NMR spec-
troscopy was utilised to probe the decomposition of
β-amidozinc reagents. NMR kinetic studies showed that the
rates of β-elimination in both THF-d8 and DMF-d7 were first
order and pointed towards a unimolecular rate-limiting step.
In addition, it was observed that the rate constant in the case
of DMF was four times smaller than that for THF. Therefore
the elimination process is significantly perturbed in DMF.
Calculation of the activation parameters led to the conclusion
that the elimination process was syn in nature, invoking an
intramolecular coordination between the carbamate and the
zinc centre (Scheme 27). DMF therefore is believed to compete
with the carbamate for zinc, thus slowing the rate of
elimination.
In 2003 it was reported that a β-amidozinc reagent was
more resistant to elimination when a better leaving group was
employed.87 Jackson and Rilatt further studied this kinetic
stability and reactivity of β-amino alkyl zinc iodides in 2008.88
They found that the N-protecting group on the zinc iodide was
critical in determining the rate of β-elimination. Boc protecting
groups were found to increase the rate of elimination, and
from this it was theorised that the carbonyl group (within the
carbamate) was competing with the ester for coordination with
zinc, leading to increased elimination. Replacing the Boc
group with a TFA group perturbed the rate of elimination. The
lower Lewis basicity of TFA on its carbonyl group helps prevent
coordination to the zinc, and thus elimination. On top of this,
it was observed that upon changing the Boc group for TFA, the
rate constant changed from being first order to second order,
indicating that the TFA elimination pathway follows a diﬀerent
mechanism from the Boc elimination. In the same report the
reactivity of the β-amino alkyl zinc iodides towards Negishi
cross-coupling was also studied. It was found that the
N-protecting group made little diﬀerence to the rate of cross-
coupling with the main factor being the proximity of the ester
from the Zn site. It was concluded that a TFA N-protecting
group oﬀers much greater stability toward β-elimination whilst
not aﬀecting the rate of Negishi cross-coupling.
Negishi cross-coupling was found to be applicable to
aqueous environments. It was reported that the presence of
tetramethylethylenediamine (TMEDA) allows the Negishi
cross-coupling of phenylalanine derivatives to be successfully
carried out in the presence of water (Scheme 28).89 Being
able to carry out Negishi reactions in water is of significant
interest to peptide chemists, as it allows the post-transla-
tional modification of peptides. It was found that the
TMEDA helps prevent protonation of the alkylzinc iodides in
water. It was proposed that the stabilisation occurs due to
the TMEDA inducing ionisation in the zinc-iodine bond.
This hypothesis was supported by evidence from tandum
mass spectometery, infrared multiphoton dissociation and
DFT calculations. Conditions for the successful synthesis of
alkylzinc iodides and subsequent Negishi coupling in water
were probed, and it was found that the use of nano zinc in
combination with TMEDA and a PdCl2(AmPhos)2 gave good
yields ranging between 28% and 73% of phenylalanine
derivatives.
Scheme 26 Total synthesis of nannocystin A, Liu et al.85
Scheme 27 Syn elimination of Boc protected amidozinc reagents.
Scheme 28 Negishi cross coupling in water of an iodo serine deriva-
tive, Jackson and co-workers.89
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Conclusions
The Negishi cross-coupling reaction has been shown to be a
highly versatile reaction allowing an expedient route to the syn-
thesis of many unnatural amino acids. Since the pioneering
work of Jackson and co-workers advances in available reagents
(e.g. new ligands) has led to an increase in substrate tolerance
and product yields. In addition mechanistic studies have
helped researchers to understand the requirements for suc-
cessful cross-couplings across a range of substrates and this
has in turn allowed access to more novel unnatural amino
acids than ever before. The ability to prepare novel aromatic,
heteroaromatic and complex amino acids opens up a myriad
of new potential applications for these motifs. For example, as
highlighted in this review, unnatural amino acids accessed via
Negishi cross-couplings have been exploited in the fields of
natural product synthesis, drug discovery, materials/polymer
chemistry and catalysis.
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